DNA Assay May Distinguish Responses to mRCC Immunotherapy
The TARDIS assay could be used in studies to identify appropriate candidates for discontinuation of immune checkpoint inhibitors.
IKCS Europe 2022
Treatment Advances Have Upped Survival in Metastatic Kidney Cancer
Investigators in Austria studied overall survival in 914 patients diagnosed with mRCC from July 1985 to September 2020.
Efficacy, Safety of Triple Combo for Advanced Kidney Cancer Probed
Study provides preliminary data on triple therapy for advanced RCC while clinicians await definitive answers from the ongoing phase 3 COSMIC-313 trial.
Kidney Cancer Metastases Effectively Treated With Robotic Radiosurgery
Investigators examined outcomes of robotic radiosurgery in patients with lung, visceral, and lymph node metastases from renal cell carcinoma.
COVID-19 mRNA Vaccine Efficacy Wanes Over Time in RCC Cases
Strategies, such as booster doses, appear warranted in this population.
Immune Checkpoint Inhibitors Prolong Survival in mRCC, Real-World Data Show
Use of immune checkpoint inhibitors for any line of treatment was beneficial, investigators reported.
Frontline Immunotherapy Appears Effective in mRCC With Poor Performance Status
Patients with poor performance status have been excluded from pivotal trials on metastatic renal cell carcinoma.
Lenvatinib+Pembrolizumab Adverse Reactions in Advanced RCC Characterized
Investigators describe the type and frequency of adverse reactions and how clinicians managed them.
- Loading...
Loading...
Next post in IKCS 2022
Loading... 
Loading...